Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fianlimab - Regeneron Pharmaceuticals

Next Previous
Drug Profile

Fianlimab - Regeneron Pharmaceuticals

Alternative Names: Anti-LAG-3 antibody - Regeneron Pharmaceuticals; REGN-3767

Latest Information Update: 21 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II/III Non-small cell lung cancer
  • Phase II Bladder cancer; Colorectal cancer; Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 21 Nov 2025 Regeneron plans a phase II trial for Malignant mesothelioma (Combination therapy, Inoperable/Unresectable) (CTIS2024-519208-29-00)
  • 03 Nov 2025 Regeneron Pharmaceuticals plans the phase II NACho trial for Colon cancer (Neo-adjuvant therapy, Combination therapy) (IV), in January 2026 (NCT07224022)
  • 03 Nov 2025 Regeneron Pharmaceuticals plans the phase II LAG-BOOST trial for Brain metastases (Combination therapy) in USA (IV) in December 2025 (NCT07223541)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top